Obesity Drug Development
5 articles on Obesity Drug Development, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
Ozempic 2.0 is Coming: A Potentially More Transformative Treatment
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
7 min read
Pfizer Clinches $10B Acquisition of Obesity Drug Firm Metsera After Bidding War
Pfizer has successfully acquired Metsera, a company specializing in obesity drug development, for $10 billion, prevailing over Novo Nordisk in a competitive bidding process. This acquisition marks Pfizer's entry into the expanding obesity drug market. Metsera's treatments are still several years from regulatory approval.
3 min read